For most of the last decade, pharmaceutical brand strategy in New Zealand has been a numbers game: build awareness across as many prescribers as possible, layer in a rep cycle, and measure outcomes quarterly. It worked when channels were scarce and attention was cheap. Neither is true anymore.
The brands gaining ground in 2026 aren’t reaching more clinicians — they’re reaching the right ones, at the right moment, with a message that’s relevant to the patient on screen. That shift, from reach to precision, is changing how pharma budgets are allocated and what “success” looks like at the end of a campaign.
Why broad-spectrum campaigns are losing ground
A traditional brand campaign treats every GP in a panel as equally likely to prescribe. In reality, prescribing is highly concentrated: a small subset of clinicians sees most of the patients in any given therapy area, and an even smaller subset is actively switching, initiating, or reviewing. Spending equally across the whole panel sends most of the budget to clinicians who were never going to change behaviour.
“The question isn’t ‘how many prescribers did we reach?’ It’s ‘how many relevant decisions did we inform?'”
